Clinical Trial

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

Withdrawn Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
Business decision
Summary
This phase Ib trial will investigate the effect of N-803 in combination with pembrolizumab and enfortumab vedotin in treating participants with urothelial cancer that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-10-14; most recent amendment 2026-03-13.
Status change: Not Yet Recruiting → Withdrawn 2026-03-13
Trial Details
NCT Number NCT07217496
Lead Sponsor Vadim S Koshkin
Collaborators: ImmunityBio, Inc.
Conditions Metastatic Urothelial Carcinoma, Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Urothelial Cancer
Start Date 2026-02-15
Primary Completion 2027-05-30 (estimated)
Study Completion 2027-05-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-17